T1	MajorClaim 1779 1912	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.
T2	Premise 1027 1188	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).
T3	Claim 1189 1284	The data offered support to the null hypothesis and therefore research hypothesis was rejected.
T4	Premise 1285 1562	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).
T5	Premise 1563 1688	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.
T6	Claim 1689 1778	The efficacy response is equal in both drugs while test drug showed more safety response.
R1	Support Arg1:T6 Arg2:T1	
R2	Support Arg1:T5 Arg2:T6	
R3	Support Arg1:T4 Arg2:T6	
R4	Support Arg1:T2 Arg2:T6	
